Internal Medicine, Hematology & Oncology · Westbrook, ME
NPI
1518183532
Since 2007
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
11 Rock Row Ste 120
Westbrook, ME, 04092
Phone (207) 303-3300
Groups this clinician bills Medicare through
Medicare paid, 2024
$4.2M
210,396 services
Medicare patients, 2024
645
Average age 75
Drug cost, 2024
$7.2M
1,460 prescriptions
Company payments, 2025
$861
From 20 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Devon L Evans was code J1439 (injection, ferric carboxymaltose, 1 mg), 55,500 times for 54 patients. In total Devon L Evans billed 210,396 services in 199 codes, and Medicare paid $4.2M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-04-17.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 55,500 | 54 | $0.88 | $49K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 19,800 | 23 | $44.74 | $886K |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 11,340 | 12 | $2.35 | $27K |
| J0897 Injection, denosumab, 1 mg | Office | 9,780 | 58 | $20.29 | $198K |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 6,300 | 14 | $38.22 | $241K |
| J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 5,000 | 23 | $35.61 | $178K |
| J9267 Injection, paclitaxel, 1 mg | Office | 4,665 | 13 | $0.08 | $371 |
| J1449 Injection, eflapegrastim-xnst, 0.1 mg | Office | 2,640 | 11 | $20.86 | $55K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,859 | 62 | $0.09 | $162 |
| 85025 Blood Count | Office | 968 | 273 | $7.60 | $7,359 |
| 99214 Office E&M - Established | Office | 957 | 289 | $94.99 | $91K |
| 80053 Clinical Chemistry | Office | 857 | 254 | $10.34 | $8,860 |
| J1626 Injection, granisetron hydrochloride, 100 mcg | Office | 840 | 37 | $0.24 | $204 |
| 36415 Venipuncture Blood Collection | Office | 735 | 242 | $8.65 | $6,358 |
| 96413 Chemotherapy Administration | Office | 390 | 119 | $98.32 | $38K |
By year: 2022 $4.0M for 211,603 services; 2023 $3.8M for 209,207 services; 2024 $4.2M for 210,396 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 968 | 273 | $7.60 | $7,359 |
| 80053 Clinical Chemistry | 857 | 254 | $10.34 | $8,860 |
| 36415 Venipuncture Blood Collection | 735 | 242 | $8.65 | $6,358 |
| 82728 Clinical Chemistry | 161 | 92 | $13.36 | $2,151 |
| 83550 Clinical Chemistry | 159 | 92 | $8.57 | $1,363 |
| 83540 Clinical Chemistry | 159 | 92 | $6.34 | $1,008 |
| 83521 Immunoassay | 90 | 23 | $16.93 | $1,523 |
| 84443 Clinical Chemistry | 89 | 43 | $16.46 | $1,465 |
| 83735 Clinical Chemistry | 80 | 41 | $6.57 | $526 |
| 82378 Clinical Chemistry | 48 | 22 | $18.25 | $876 |
Medicare prescription drug claims, 2024
In 2024, the drug Devon L Evans prescribed most often to Medicare patients was Hydroxyurea, with 82 prescriptions and refills. In total Devon L Evans wrote 1,460 Medicare prescriptions that cost $7.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxyurea Generic | 82 | 124 | 17 | $1,860 |
| Anastrozole Generic | 70 | 154 | 19 | $1,547 |
| Prednisone Generic | 64 | 82 | 29 | $267 |
| Revlimid Lenalidomide | 51 | 51 | Under 11 | $808K |
| Levothyroxine Sodium Generic | 48 | 77 | 13 | $189 |
| Gabapentin Generic | 43 | 44 | 11 | $1,093 |
| Darzalex Faspro Daratumumab-Hyaluronidase-Fihj | 43 | 43 | Under 11 | $403K |
| Erleada Apalutamide | 42 | 42 | Under 11 | $623K |
| Ondansetron Odt Ondansetron | 37 | 37 | 26 | $561 |
| Imatinib Mesylate Generic | 34 | 36 | Under 11 | $18K |
| Tamoxifen Citrate Generic | 33 | 51 | Under 11 | $341 |
| Creon Lipase/Protease/Amylase | 31 | 51 | Under 11 | $85K |
| Verzenio Abemaciclib | 31 | 31 | Under 11 | $497K |
| Prochlorperazine Maleate Generic | 30 | 30 | 15 | $225 |
| Dexamethasone Generic | 30 | 38 | 22 | $708 |
Brand drugs: 581 claims; generic drugs: 879 claims; opioid claims: 35.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Devon L Evans $861 ($861 in general payments such as food, travel and fees) from 20 companies. The largest payer was Abbvie Inc. with $143.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 6 | $143 |
| AstraZeneca Pharmaceuticals LP AZN | 5 | $131 |
| Daiichi Sankyo Inc. 4568.T | 4 | $86.33 |
| Janssen Biotech, Inc. JNJ | 3 | $84.76 |
| ASD Specialty Healthcare, LLC | 1 | $56.42 |
| E.R. Squibb & Sons, L.L.C. BMY | 2 | $47.69 |
| Novocure Inc. NVCR | 1 | $40.55 |
| Merck Sharp & Dohme LLC MRK | 2 | $37.17 |
| Astellas Pharma US Inc 4503.T | 1 | $31.61 |
| Novartis Pharmaceuticals Corporation NVS | 2 | $29.76 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.